The relationship between anti-HPV-16 IgG seropositivity and cancer of the cervix, anogenital organs, oral cavity and pharynx, oesophagus and prostate in a black South African population

被引：41

作者：

Sitas F. ^{[1
,2
,3
]}

Urban M. ^{[1
]}

Stein L. ^{[1
]}

Beral V. ^{[4
]}

Ruff P. ^{[5
]}

Hale M. ^{[5
,6
]}

Patel M. ^{[5
]}

O'Connell D. ^{[2
]}

Yu X.Q. ^{[2
]}

Verzijden A. ^{[7
]}

Marais D. ^{[8
]}

Williamson A.-L. ^{[8
]}

机构：

[1] Cancer Epidemiology Research Group, National Health Laboratory Service, Johannesburg, 2000

[2] Research Division, Cancer Council NSW, Kings Cross, 1340, NSW

[3] Schools of Public Health, Universities of Sydney and NSW, Sydney, NSW

[4] Epidemiology Unit, Cancer Research UK, Oxford

[5] Faculty of Health Sciences, University of the Witwatersrand, Johannesburg

[6] Anatomical Pathology Department, National Health Laboratory Service, Johannesburg

[7] Dept. of Epidemiology and Biostatistics, Radboud University, Nijmegen Medical Centre, Nijmegen

[8] Division of Medical Virology, Institute of Infectious Disease and Molecular Medicine, University of Cape Town Medical School, Observatory, Cape Town

来源：

Infectious Agents and Cancer | / 2卷 / 1期

关键词：

Oral Cavity; Penile Cancer; Pharyngeal Cancer; High Antibody Level; ELISA Optical Density;

D O I：

10.1186/1750-9378-2-6

中图分类号：

学科分类号：

摘要：

Background: Human papillomavirus type 16 (HPV-16) infection is an important cause of cervical cancer, other anogenital cancers and, possibly, some oral and pharyngeal cancers. The association of HPV-16 with oesophageal and with prostate cancers has not been firmly established. Methods: We analysed sera from 3,757 HIV seronegative black South Africans using an anti-HPV IgG enzyme-linked immunosorbent assay (ELISA). The subjects were recruited from 1995 to 2000 as part of an ongoing cancer case control study. Cases were patients with newly diagnosed cancers of the cervix (n = 946), other anogenital organs (n = 80), the oral cavity and pharynx (n = 102), the oesophagus (n = 369) or the prostate (n = 205). The comparison group consisted of 2,055 age and sex-matched patients randomly selected from the same data base, diagnosed at the same hospitals, but with a vascular disease or with a cancer unrelated to HPV infection. Subjects' sera were randomly and blindly allocated onto ELISA plates. Optical density (OD) levels of anti-HPV-16 IgG of > 0.45 and ≥ 0.767 were taken to be cut-offs for negative, medium and high antibody levels. Results: After adjustment for potential confounders, cancer types that showed a statistically significant association with increased anti-HPV-16 IgG antibody (Ab) levels were cancer of the cervix (OR for medium Ab levels = 1.6, and for high = 2.4, p < 0.0001), cancers of other anogenital organs (OR for medium or high Ab levels = 2.5, p = 0.002), and cancer of the oesophagus (OR for medium Ab = 1.3, and high Ab levels = 1.6 p = 0.002). Cancers of the oral cavity and pharynx showed a borderline significant association in the unadjusted model (p = 0.05) but after adjustment for confounding the trend in relation to Ab levels was positive but not statistically significant (OR for medium Ab = 1.1, and high Ab = 1.5 p = 0.13). Prostate cancer was not associated with HPV-16 seropositivity (OR for medium Ab level = 1.4, and for high Ab level = 1.3, p = 0.3). Conclusion: If there is indeed an association between HPV-16 and oesophageal and possibly also some oral cavity and pharyngeal cancers, then emerging HPV vaccines may also reduce, at least in part, the incidence of these leading cancer types.

引用

共 39 条

[1]

Mqoqi N., Kellett P., Sitas F., Jula M., Incidence of histologically diagnosed cancer in South Africa, Johannesburg, National Cancer Registry of South Africa, (1998)

[2]

IARC monographs on the evaluation of carcinogenic risks to humans

[3]

human papillomaviruses, 64, (1995)

[4]

Herrero R., Castellsague X., Pawlita M., Lissowska J., Kee F., Balaram P., Rajkumar T., Sridhar H., Rose B., Pintos J., Fernandez L., Idris A., Sanchez M.J., Nieto A., Talamini R., Tavani A., Bosch F.X., Reidel U., Snijders P.J., Meijer C.J., Viscidi R., Munoz N., Franceschi S., Human papillomavirus and oral cancer: The International Agency for Research on Cancer multicenter study, J Natl Cancer Inst, 95, pp. 1772-1783, (2003)

[5]

Syrjanen K.J., HPV infections and oesophageal cancer, J Clin Pathol, 55, pp. 721-728, (2002)

[6]

Syrjanen S., Human papillomavirus (HPV) in head and neck cancer, J Clin Virol, 32, SUPPL. 1, (2005)

[7]

Williamson A.L., Jaskiesicz K., Gunning A., The detection of human papillomavirus in oesophageal lesions, Anticancer Res, 11, pp. 263-265, (1991)

[8]

Lagergren J., Wang Z., Bergstrom R., Dillner J., Nyren O., Human papillomavirus infection and esophageal cancer: A nationwide seroepidemiologic case-control study in Sweden, J Natl Cancer Inst, 91, pp. 156-162, (1999)

[9]

Rosenblatt K.A., Carter J.J., Iwasaki L.M., Galloway D.A., Stanford J.L., Serologic evidence of human papillomavirus 16 and 18 infections and risk of prostate cancer, Cancer Epidemiol Biomarkers Prev, 12, pp. 763-768, (2003)

[10]

Adami H.O., Kuper H., Andersson S.O., Bergstrom R., Dillner J., Prostate cancer risk and serologic evidence of human papilloma virus infection: A population-based case-control study, Cancer Epidemiol Biomarkers Prev, 12, pp. 872-875, (2003)

← 1 2 3 4 →